Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EPS (Weighted Average and Diluted) (2016 - 2025)

Historic EPS (Weighted Average and Diluted) for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $0.95.

  • Haemonetics' EPS (Weighted Average and Diluted) rose 2837.84% to $0.95 in Q4 2025 from the same period last year, while for Dec 2025 it was $3.63, marking a year-over-year increase of 4291.34%. This contributed to the annual value of $3.31 for FY2025, which is 4433.03% up from last year.
  • Haemonetics' EPS (Weighted Average and Diluted) amounted to $0.95 in Q4 2025, which was up 2837.84% from $0.81 recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' EPS (Weighted Average and Diluted) peaked at $1.14 during Q1 2025, and registered a low of -$0.22 during Q2 2021.
  • For the 5-year period, Haemonetics' EPS (Weighted Average and Diluted) averaged around $0.54, with its median value being $0.62 (2022).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 16325.04% in 2021, then skyrocketed by 52222.22% in 2022.
  • Quarter analysis of 5 years shows Haemonetics' EPS (Weighted Average and Diluted) stood at $0.29 in 2021, then surged by 120.69% to $0.64 in 2022, then decreased by 4.69% to $0.61 in 2023, then rose by 21.31% to $0.74 in 2024, then increased by 28.38% to $0.95 in 2025.
  • Its last three reported values are $0.95 in Q4 2025, $0.81 for Q3 2025, and $0.7 during Q2 2025.